Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Venous Thromboembolism | Unmet Need | US/EU |2018

Login to access report north_east
Contact sales account_box

MARKET OUTLOOK

Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), represents a significant medical and economic burden. Although, the launch of the NOACs signifies an important milestone for the treatment and secondary prophylaxis of VTE, there are still some areas of unmet need that remain underserved in this patient population. This report examines current treatment performance against treatment goals in the treatment and secondary prophylaxis of DVT and PE from the perspective of emergency room physicians and hematologists. This report also offers insight from these physicians on existing unmet needs for DVT and PE, while our target product profile conjoint simulator demonstrates how various attributes influence these physicians’ prescribing decisions.

QUESTIONS ANSWERED

  • What are the treatment drivers and goals for VTE?
  • What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for VTE?
  • What are the prevailing areas of unmet need and opportunity in VTE?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European emergency room physicians and hematologists for a hypothetical new VTE drug?

PRODUCT DESCRIPTION

Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered:United States, France, Germany, and United Kingdom.

Primary research: Survey of 60 U.S. and 31 European emergency room physicians and hematologists fielded in May 2018.

Key companies: Bayer, Pfizer, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, and Janssen Pharmaceuticals.

Key drugs: Pradaxa, Xarelto, Eliquis, and Savaysa/Lixiana.

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Post-Traumatic Stress Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Post-Traumatic Stress Disorder (US)
Multiple guidelines recommend treating post-traumatic stress disorder (PTSD) first with psychotherapy. However, such approaches do not suffice for many patients, necessitating the use of…
north_east
Report
Type 1 Diabetes – Current Treatment – Treatment Algorithms: Claims Data Analysis – Type 1 Diabetes (US)
Intensive insulin regimens have proven effective in delaying the progression of complications associated with untreated or poorly treated type 1 diabetes (T1D). Thus, insulin remains the…
north_east
Report
Postpartum Depression – Current Treatment – Treatment Algorithms: Claims Data Analysis – Postpartum Depression (US)
Postpartum depression (PPD) refers to depression experienced by women after childbirth. The PPD drug market consists of very limited treatment options specifically approved for PPD, so drugs used…
north_east
Report
Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus. It consists of deep vein thrombosis (DVT) and pulmonary embolism (PE), depending on the vein affected. Current…
north_east
Report
Uterine Fibroids – Current Treatment – Treatment Algorithms: Claims Data Analysis – Uterine Fibroids (US)
Treatment for uterine fibroids includes pharmacological approaches and surgical procedures. NSAIDs help alleviate the pain but do not reduce the fibroids’ size. Progestins (e.g., norethindrone,…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east